638 Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Asian patients with moderate to severe plaque psoriasis: Absolute psoriasis area and severity index outcomes in the phase 3 POETYK PSO-3 trial

Deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, is approved in the US, Japan, and other countries for the treatment of adults with moderate-to-severe plaque psoriasis. The 52-week, double-blind phase 3 POETYK PSO-3 trial (NCT04167462) in patients with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea demonstrated the significant superiority of deucravacitinib (n=146) vs placebo (n=74) at Week 16 in ≥75% reduction from baseline in PASI (PASI 75; 68.8% vs 8.1%, respectively) and static Physicians Global Assessment score of 0 (clear) or 1 (almost clear; sPGA 0/1; 55.6% vs 6.8%). We report further analyses of PASI improvements in PSO-3. Mean baseline PASI was similar in patients receiving deucravacitinib (24.6) and placebo (24.4). Adjusted mean change in PASI from baseline at Week 16 was significantly greater with deucravacitinib vs placebo (−16.8 vs −0.4, respectively; P<0.0001). Higher proportions of deucravacitinib vs placebo patients achieved clinically meaningful outcomes of absolute PASI ≤1 (17.1% vs 0%), ≤2 (35.6% vs 0%), ≤3 (49.3% vs 1.4%), ≤4 (59.6% vs 5.4%), and ≤5 (64.4% vs 6.8%) at Week 16; improvements were maintained through Week 52. Placebo patients who crossed over to deucravacitinib after Week 16 showed similar improvements at Week 52 as those treated with deucravacitinib from Day 1. These results show that Asian patients with moderate to severe plaque psoriasis treated with deucravacitinib achieved clinically meaningful absolute PASI outcomes that were superior to placebo.